The short version of GLP-1 receptor fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-04-13. Anything still debated is marked as such rather than presented as settled.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Body composition is assessed with dual-energy X-ray absorptiometry or comparable methods, which separate fat mass from lean mass. Reported losses include both compartments, and the ratio between them is a subject of ongoing analysis rather than a settled result. Waist circumference, blood pressure, and lipid panels are collected as supporting measures. Resting energy expenditure and substrate oxidation are measured in smaller mechanistic studies, where glucagon receptor activity is expected to matter. These substudies are typically short and small, so their findings carry wide uncertainty.
Interpretation depends on study phase and duration. Phase 2 programs are powered for weight and safety signals, not for cardiovascular or renal outcomes, which require event-driven designs. Gastrointestinal events such as nausea, diarrhea, vomiting, and constipation are the most frequently reported adverse effects and tend to cluster around dose escalation. Small increases in heart rate have been described. Because follow-up after treatment discontinuation is limited, questions about weight regain and durability are open rather than answered.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Contains non-natural residues |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist profile |
| Route of administration | Subcutaneous injection | In clinical trial settings |
| Development status | Investigational | Not approved in major markets |
| Approximate molecular mass | About 4.7 kDa | Peptide-scale molecule |
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Several questions remain unresolved. It is not yet known whether the compound reduces cardiovascular events or mortality, because outcome studies require long follow-up. The durability of weight reduction after treatment withdrawal is uncertain, and rebound has been observed with other incretin-based therapies. Long-term safety data covering several years are limited. Effects in adolescents, in pregnancy, and in people with significant kidney or liver impairment have not been characterized in published reports.
Randomized studies of retatrutide measure change in body weight as a percentage of baseline, along with absolute weight loss. Glycemic endpoints include hemoglobin A1c and fasting plasma glucose. Investigators also track blood pressure, lipid fractions, and liver fat content to characterize effects beyond weight alone. Trial designs typically use double-blind, placebo-controlled groups with periodic dose escalation, and they record adverse events throughout both treatment and follow-up periods.
These included statements that God emits a cosmic broadcast of electromagnetic waves that living creatures can receive when their neural networks are enabled by DMT; that adding DMT allows people to see otherwise invisible spirits and guardian angels; that schizophrenia and autism result from an over-abundance of bioavailable DMT and should be unified under the term “Autiphrenia,” with those affected described as geniuses created to lead humanity; that vaporizing DMT had cured his brain cancer; that staring at the sun promotes DMT production in the pineal gland; and that DMT could cure other diseases. He invited cancer patients to his ranch in the Lake View Terrace area of Los Angeles to try the substance. In a video recorded after the cancer claim was questioned, Cantelmo stated that he had never had any form of cancer and that the reference was metaphorical, describing atheism as the “worst form of cancer.” His brother Craig and other family members confirmed he had never been diagnosed with cancer.
== Drug therapy == RTKs have become an attractive target for drug therapy due to their implication in a variety of cellular abnormalities such as cancer, degenerative diseases and cardiovascular diseases. The United States Food and Drug Administration (FDA) has approved several anti-cancer drugs caused by activated RTKs. Drugs have been developed to target the extracellular domain or the catalytic domain, thus inhibiting ligand binding, receptor oligomerization. Herceptin, a monoclonal antibody that is capable of binding to the extracellular domain of RTKs, has been used to treat HER2 overexpression in breast cancer.
Hence, in rats, vosilasarm is a potent full agonist of the levator ani muscle but a partial agonist and antagonist of the prostate and seminal vesicles, and is strongly selective for stimulating the levator ani muscle over the prostate gland. In young male cynomolgus monkeys, vosilasarm, at oral doses of 0.01 mg/kg/day, 0.1 mg/kg/day, and 1 mg/kg/day for 28 days, dose-dependently stimulated body weight (+10% at ≥0.1 mg/kg/day) and numerically increased lean body mass. The lack of statistical significance was likely due to the small sample sizes per dosing group (n=3 each). No data on vosilasarm and lean body mass in humans have been published as of 2022.
In the laboratory it is a common precipitant and cryoprotectant in protein crystallography. Since hexylene glycol is compatible with polar and nonpolar molecules, it competes with the solvent in a crystallography experiment causing the protein to precipitate. Hexylene glycol is so effective in protein crystallography because its amphiphilic nature and small, flexible structure allows it to bind to many different locations on a protein secondary structure including alpha helices and beta sheets. When hexylene glycol binds to these different locations, water is removed and the protein crystals anneal, which prevents ice formation during cryocrystallography techniques. Incorporation of hexylene glycol into solution has been known to improve the resolution of X-ray diffraction making protein structures easily identifiable. Additionally hexylene glycol is not a strong denaturing agent and thus does not significantly alter the structure of a protein during the crystallography procedure. Hexylene glycol is also used as a lubricant for polishing specimens in metallography. Like related diols, it forms borate esters.
Sources: en.wikipedia.org
Some groups of people have specialized transfusion requirements. Fetuses, very low-birth-weight infants, and immunocompromised people are at risk for developing severe infection with cytomegalovirus (CMV)―an opportunistic pathogen for which approximately 50% of blood donors test positive―and may be transfused with CMV-negative blood to prevent infection. Those who are at risk of developing graft-versus-host disease, such as bone marrow transplant recipients, receive blood that has been irradiated to inactivate the T lymphocytes that are responsible for this reaction. People who have had serious allergic reactions to blood transfusions in the past may be transfused with blood that has been "washed" to remove plasma. The history of the patient is also examined to see if they have previously identified antibodies and any other serological anomalies. A direct antiglobulin test (Coombs test) is also performed as part of the antibody investigation. Donor blood is generally screened for transfusion-transmitted infections such as HIV. As of 2018, the World Health Organization reported that nearly 100% of blood donations in high- and upper-middle-income countries underwent infectious disease screening, but the figures for lower-middle-income and low-income countries were 82% and 80.3% respectively.
In the periodic table, nobelium is located to the right of the actinide mendelevium, to the left of the actinide lawrencium, and below the lanthanide ytterbium. Nobelium metal has not yet been prepared in bulk quantities, and bulk preparation is currently impossible. Nevertheless, a number of predictions and some preliminary experimental results have been done regarding its properties. The lanthanides and actinides, in the metallic state, can exist as either divalent (such as europium and ytterbium) or trivalent (most other lanthanides) metals. The former have fns2 configurations, whereas the latter have fn−1d1s2 configurations. In 1975, Johansson and Rosengren examined the measured and predicted values for the cohesive energies (enthalpies of crystallization) of the metallic lanthanides and actinides, both as divalent and trivalent metals. The conclusion was that the increased binding energy of the [Rn]5f136d17s2 configuration over the [Rn]5f147s2 configuration for nobelium was not enough to compensate for the energy needed to promote one 5f electron to 6d, as is true also for the very late actinides: thus einsteinium, fermium, mendelevium, and nobelium were expected to be divalent metals, although for nobelium this prediction has not yet been confirmed.
Hazard research is published: a study indicates common food allergies are not benign but are associated with increased risk of cardiovascular mortality (9 Nov), in a commentary, scientists warn that to "reduce plastic pollution efficiently and economically, policy should prioritize regulating and reducing upstream production rather than downstream pollution cleanup" as "popularized by The Ocean Cleanup" (9 Nov), social unconnectedness confirmed as likely substantial mortality risk factor using UK Biobank data (10 Nov), nanoplastic pollution and consumption identified as a likely Parkinson's disease risk factor (17 Nov), a review cautions "robust evidence has yet to emerge that [air treatment technologies] are effective at reducing respiratory or gastrointestinal infections in real world settings" (20 Nov), a content analysis of packaging marketing of infant and toddler foods in supermarkets suggests protection of young children's diets from harmful influence of food marketing is needed (28 Nov), a preprint suggests some large language models have an 'extractable memorization' flaw by which training data can be extracted at affordable costs by queries (28 Nov).
===== Iguania ===== Clade Acrodonta Family Agamidae Pogona vitticeps, Central bearded dragon, (2015) Clade Pleurodonta Family Dactyloidae Anolis carolinensis, Carolina anole, (2011) Family Phrynosomatidae Phrynosoma platyrhinos, Dessert horned lizard, (2021) Phrynosoma cornutum, Texas horned lizard, (2021) Sceloporus undulatus, Eastern fence lizard (2021)
== Early life == Gerald Ernst (Jerry) Gallwas was born in Whittier, California, the only child of Ernst and Lois Gallwas. Gallwas' father held many jobs, including farmer, iron worker, and commercial fisherman. His mother was a schoolteacher. Both parents were outdoor enthusiasts. Gallwas, a native of California, first showed an interest in climbing in junior high school. Using a Sierra Club publication drawing as a guide, he practiced rappelling on a hemp rope. In 1950, Gallwas and his family vacationed in Yosemite National Park. On the front of Best Studio, now the Ansel Adams Gallery, Gallwas spied a picture of John Salathé standing on the tip of the Lost Arrow taking a photograph of his climbing partner, Anton Nelson, as Nelson was rappelling. Gallwas imagined one day taking a photo where Salathé stood. In 1954, Gallwas fulfilled that dream by completing the 5th ascent of the spire with Wayne Merry.
Sources: en.wikipedia.org
== External links == Emil Fischer on Nobelprize.org including his Nobel Lecture Nobel Lecture, 12 December 1902 Syntheses in the Purine and Sugar Group Eminent Chemists of Our Time By Benjamin Harrow pages 216–239, published 1920 by Von Nostrand Company at books.google.com. Aders Plimmer, R. H. (July 1907). "The work of Emil Fischer and his school on the chemistry of the proteins". Science Progress in the Twentieth Century. 2 (5): 88–120. Guide to the Emil Fischer Papers at The Bancroft Library Text-book of Physiological Chemistry in Thirty Lectures by Emil Abderhalden, translated by William Thomas Hall and George Defren; published 1908 by Wiley Company, has many technical references to Fischer's work in Chemistry. American Journal of Diseases of Children 1911 volume 2 by the American Medical Association also refers to Fischer's work. An Introduction to the History of Medicine: With Medical Chronology by Fielding Hudson Garrison, page 708 refers to Fischer and Merings discovery of the drugs veronal(1904) and proponal(1905), published 1921 by Saunders Company. 1914 Year Book of the American Pharmaceutical Association, page 438 abstracts Fischer and Strauss's work on Phenol-Glucosides – Synthetic Production from Berlin d.D Chem. Germany, page 45(1912) No. 12. Texts on Wikisource: "Fischer, Emil". New International Encyclopedia. 1905. "Fischer, Emil". Encyclopædia Britannica (11th ed.). 1911. "Fischer, Emil". Encyclopedia Americana. 1920.
== Chemistry == Naloxone, also known as N-allylnoroxymorphone or as 17-allyl-4,5α-epoxy-3,14-dihydroxymorphinan-6-one, is a synthetic morphinan derivative and was derived from oxymorphone (14-hydroxydihydromorphinone), an opioid analgesic. Oxymorphone, in turn, was derived from morphine, an opioid analgesic and naturally occurring constituent of the opium poppy. Naloxone is a racemic mixture of two enantiomers, (–)-naloxone (levonaloxone) and (+)-naloxone (dextronaloxone), only the former of which is active at opioid receptors. The drug is highly lipophilic, allowing it to rapidly penetrate the brain and to achieve a far greater brain to serum ratio than that of morphine. Opioid antagonists related to naloxone include cyprodime, nalmefene, nalodeine, naloxol, and naltrexone.
His name is also removed from the Roll of the Peerage, but he is still eighth in the line of succession and remains a Counsellor of State. Starmer announces that Chancellor Rachel Reeves will face no further action for failing to obtain the relevant licence before renting out her family home, but rebukes her for not providing him with all of the information when the story about her broke. Dartford Borough Council councillor James Buchan defects from Reform UK to the Conservatives after becoming "uncomfortable" with his former party.
Their diet in the wild primarily consists of dark green vegetables such as grasses and clovers, and excessive carrot consumption is unhealthy for them due to containing high levels of sugar. Tomato juice and sauce are ineffective at neutralizing the odor of a skunk. Rather, due to olfactory fatigue, a person sprayed by a skunk loses sensitivity to the smell over time. Effective treatments for skunk odor involve artificial compounds rather than household remedies. There is no such thing as an "alpha" in a wolf pack. An early study that coined the term "alpha wolf" had observed only unrelated adult wolves living in captivity. In the wild, wolf packs operate like families: parents are in charge until the young grow up and start their own families, and younger wolves do not overthrow an "alpha" to become the new leader. The phases of the Moon have no effect on the vocalizations of wolves, and wolves do not howl at the Moon. Wolves howl to assemble the pack usually before and after hunts, to pass on an alarm particularly at a den site, to locate each other during a storm, while crossing unfamiliar territory, and to communicate across great distances.
=== Definition === Some sources do not consider "pelvic floor" and "pelvic diaphragm" to be identical, with the "diaphragm" consisting of only the levator ani and coccygeus, while the "floor" also includes the perineal membrane and deep perineal pouch. However, other sources include the fascia as part of the diaphragm. In practice, the two terms are often used interchangeably.
Sources: en.wikipedia.org
It is designed as a triple agonist acting on the GLP-1, GIP, and glucagon receptors. This combination is intended to influence appetite, insulin secretion, and energy expenditure. Single-receptor and dual-receptor compounds act on a narrower set of targets.
No. It remains investigational, and phase 3 results have not been fully published or reviewed by regulators. Official approval status should be confirmed through regulatory agencies rather than secondary sources.
The added glucagon receptor activity is the main difference in its mechanism. Whether that addition produces meaningful benefits in clinical outcomes is still being studied. Comparisons between compounds rest largely on indirect rather than head-to-head trial data.
A responder analysis counts participants who cross a threshold, such as five or ten percent weight loss. It complements average percent change by showing how widely results are distributed. The two measures can diverge when a subset of participants loses a large amount.